{"id":"NCT03518086","sponsor":"Eli Lilly and Company","briefTitle":"An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-18","primaryCompletion":"2021-01-21","completion":"2024-05-15","firstPosted":"2018-05-08","resultsPosted":"2022-02-28","lastUpdate":"2025-05-31"},"enrollment":1281,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"Mirikizumab","otherNames":["LY3074828"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo Intravenous (IV) Every 4 Weeks (Q4W)","type":"PLACEBO_COMPARATOR"},{"label":"300 Milligram (mg) Mirikizumab IV Q4W","type":"EXPERIMENTAL"},{"label":"Placebo IV Q4W Maximum Extended Enrollment (ME2)","type":"PLACEBO_COMPARATOR"},{"label":"300 mg Mirikizumab IV Q4W ME2","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.","primaryOutcome":{"measure":"Percentage of Participants With Clinical Remission at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo IV Q4W","deltaMin":13.3,"sd":null},{"arm":"300 mg Mirikizumab IV Q4W","deltaMin":24.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.00006"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":502,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","China","Croatia","Czechia","Denmark","France","Germany","Hungary","India","Ireland","Israel","Italy","Japan","Latvia","Lithuania","Malaysia","Mexico","Netherlands","Poland","Romania","Russia","Serbia","Slovakia","South Korea","Spain","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["40591171","40589947","39448057","38869019","38313767","38034882","37610533","37379135","37057827"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/282m4A1tIAKOegkOgG02mg"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":321},"commonTop":["Anaemia","Upper respiratory tract infection","Colitis ulcerative"]}}